Marsha is sought by both innovator and generic pharmaceutical and biopharmaceutical companies for assistance with intellectual property issues related to their pharmaceutical products, including freedom-to-operate analyses and lifecycle management strategies.
Overview
Marsha Rose Gillentine, Ph.D., is a director in Sterne Kessler’s Biotechnology & Chemical and Trial & Appellate Practice Groups. Marsha is primarily focused on the pharmaceutical industry. She is intimately familiar with the Hatch-Waxman Act and Biologics Price Competition and Innovation Act and understands patent litigation strategy in the context of the statutory schemes and Patent Office Litigation. Marsha is sought by both innovator and generic pharmaceutical and biopharmaceutical companies for assistance with intellectual property issues related to their pharmaceutical products, including freedom-to-operate analyses and lifecycle management strategies.
Marsha has provided hundreds of patentability, noninfringement, and invalidity opinions. She has rendered opinions in a variety of technology areas including: small molecules, therapeutic antibodies, polymorphs, salts, synthesis, pharmaceutical formulations, and pharmacokinetics.
Marsha also assists clients in implementing lifecycle management strategies, including those for precision medicine patent portfolios. Her practice encompasses both domestic and foreign patent prosecution, including patent drafting and patent prosecution. She has drafted and prosecuted patents related to various pharmaceutical issues. For example, Marsha has prosecuted patents related to small molecules, polymorphs, chemical synthesis, pharmaceutical formulations, methods of treatment, drug delivery devices, animal models, vaccines, polymers, genes, gene expression systems, proteins, and antibodies.
Marsha has been involved in multiple pharmaceutical patent litigations brought under the Hatch-Waxman Act, and has also assisted clients with proceedings before the U.S. Patent Trial and Appeal Board (PTAB).
Marsha was one of the first recipients of the Sterne, Kessler, Goldstein & Fox Intellectual Property Scholarship at the George Mason University School of Law, where she was also a member of the Moot Court Board. She earned her Ph.D. in biological chemistry from the University of North Carolina – Chapel Hill, and her B.S., cum laude, in Chemistry from Berry College.
Education
- J.D., George Mason University Antonin Scalia Law School, cum laude
- Ph.D., Biological Chemistry, University of North Carolina at Chapel Hill
- B.S., Chemistry, Berry College, cum laude